Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

PSDisrupt AI-driven discovery broad-spectrum antivirals targeting Nucleocytoviricota factories via phase separation modulation

Coordinator
Centre National De La Recherche Scientifique CNRS, France
Runs
1 October 2025 to 31 March 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101247194

What the project is doing

In the project's own words, from its summary on CORDIS.

The phylum Nucleocytoviricota includes (re-)emerging dsDNA viruses of major concern, such as monkeypox virus (mpox) and African swine fever virus (ASFV). Despite their economic and public health impact, no formally approved antivirals exist for these pathogens. Viral factories (membrane-less organelles essential for replication) are highly conserved across Nucleocytoviricota, presenting an attractive and untapped target for antiviral intervention.

PSDisrupt builds on findings from the ERC-funded ViDaMa project, which identified scaffold proteins governing phase separation in viral factories. These proteins share a conserved ""molecular grammar"" essential for condensate formation. Disrupting this process is expected to broadly inhibit viral replication while minimizing the development of resistance. This PoC project will design phase-separation grammar-targeting antivirals using AI-driven pipelines.

Deep learning models will enable the screening of ultra-large chemical spaces to identify: (i) broad-spectrum inhibitors targeting conserved scaffold proteins across Nucleocytoviricota, and/or (ii) virus-specific antivirals for mpox and ASFV.PSDisrupt’s translational goal is to design and advance lead compounds into preclinical validation and assess their commercial potential. We will:-Discover and design drugs by leveraging high throughput screens and deep learning-based algorithms.-Perform biophysical and cellular assays to validate compound efficacy.-Establish IP protection for novel inhibitors.-Engage with pharmaceutical and biotech partners for licensing and further development.

By bridging virology and AI-driven drug design, PSDisrupt pioneers a novel antiviral strategy with broad applications beyond infectious diseases. The AI framework could be adapted to target phase separation in diverse pathological conditions, including cancer, neurodegeneration, and other condensate-associated diseases, significantly expanding its biomedical and commercial impact.""

Topics

Who is involved

OrganisationCityCountryRole
Centre National De La Recherche Scientifique CNRSParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI